2. Academic Validation
  3. Structure-based design of potent CDK1 inhibitors derived from olomoucine

Structure-based design of potent CDK1 inhibitors derived from olomoucine

  • J Comput Aided Mol Des. 2000 Jul;14(5):403-9. doi: 10.1023/a:1008115004986.
P Furet 1,  J Zimmermann,  H G Capraro,  T Meyer,  P Imbach
Affiliations

Affiliation

  • 1 Novartis Pharma Inc., Oncology Research Department, Basel, Switzerland. pascal.furet@pharma.novartis.com
PMID: 10896313 DOI: 10.1023/a:1008115004986
Abstract

Cyclin-dependent kinase 1 (CDK1), an enzyme participating in the regulation of the cell cycle, constitutes a possible target in the search for new antitumor agents. Starting from the purine derivative olomoucine and following a structure-based approach, potent inhibitors of this enzyme were rapidly identified. The molecular modeling aspects of this work are described.

Figures
Products